The price target for Hims & Hers has been reduced, reportedly due to the company's transition related to GLP-1 medications.

Hims & Hers has announced a shift in its business model, a development that comes after a recent deal involving Novo.

Yahoo Finance highlights two S&P 500 stocks for investors to monitor this week, following an unexpected development with Hims & Hers stock.

Hims & Hers experienced its strongest weekly stock gain following the announcement of a deal with Novo Nordisk.

Several stocks, including Bumble, Hims & Hers Health, Blue Owl, and Netskope, are making significant moves in premarket trading, indicating potential volatility for the upcoming trading session.

An asset manager has divested its holdings in Hims & Hers Health, indicating a significant change in investment strategy for the healthcare company's stock.

Novo Nordisk to Sell Weight-Loss Drugs Through Hims & Hers  WSJ

Hims & Hers is being highlighted as a potential direct-to-consumer health 'moonshot' investment opportunity.

Hims & Hers Health, Inc. has provided a summary of its earnings call for the fourth quarter of 2025.

Hims & Hers (HIMS) has released its earnings call transcript, providing details on the company's financial performance and future outlook.

This article provides a summary of significant corporate deals and transactions that occurred this week, featuring companies such as Visa, Hims & Hers Health, and Salesforce.

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, expanding its health and wellness offerings.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Deutsche Bank expressed near-term growth concerns for Hims & Hers Health, Inc. (HIMS) following the reversal of its GLP-1 launch.

Hims & Hers is making a strategic move to disrupt the pharmaceutical and pharmacy industries by focusing on making longevity treatments more affordable and accessible.

Hims & Hers (HIMS) shares soared by 6% after the company announced its entry into the lucrative $200-billion weight loss market.

Hims & Hers Health has announced it is now selling Novo Nordisk's popular weight-loss medications, Wegovy and Ozempic, expanding access to these treatments.

Hims & Hers (HIMS) is experiencing renewed analyst optimism following a resolution related to Novo Nordisk.

These are the stocks posting the largest moves in early trading.

Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration  AP News

Hims & Hers stock experienced a significant 40% surge following a 'GLP-1 truce'.

An analysis suggests that Hims & Hers Health's expansion into the GLP-1 business may not materialize quickly enough to mitigate associated risks.

A Yahoo Finance article highlights Hims & Hers as a significant telehealth growth story that younger investors should consider, focusing on the company's financial performance and market potential.

These are the stocks posting the largest moves in early trading.

The market saw Hims & Hers stock slide while Domino's rose, as investors anticipate a crucial update from Nvidia amidst a busy earnings season.

Hims & Hers Health, Inc. (HIMS) has announced a 2026 revenue forecast that surpasses market estimates, indicating strong projected financial performance.

Analysts are projecting a significant upside for Hims & Hers stock despite its current performance, with some seeing nearly 150% potential growth.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, expanding its presence in the health and wellness market.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion, signaling a major expansion in its market presence.

Hims & Hers is investing more than $1 billion to expand its global footprint, including a significant acquisition of an Australia-based telehealth company.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers' strategy involving GLP-1 pills has reportedly backfired, leading to increased scrutiny and a crackdown on drug compounders.

Despite a 48% selloff this month, Wall Street analysts see an 84% upside potential for Hims & Hers (HIMS) stock.

A new partnership with Novo is fueling long-term optimism for Hims & Hers Health, Inc. (HIMS), suggesting positive future growth prospects for the company.

Hims & Hers (HIMS) stock experienced an 8.86% tumble, driven by a broader market downturn and significant profit-taking by investors.

A new deal between pharmaceutical giant Novo Nordisk and health platform Hims & Hers is expected to yield positive outcomes for the stock performance of both companies.

Barclays has increased its price target for Hims & Hers (HIMS) to $29 following the clearance of a legal overhang related to the Novo Nordisk deal, which has also led to a surge in Hims & Hers stock.

Several stocks, including Hims & Hers Health, oil stocks, and Live Nation Entertainment, are making significant moves in premarket trading, with Hims & Hers specifically upgraded to Buy from Hold by Needham.

Hims & Hers stock is currently challenging its 50-day moving average, prompting investors to consider if this indicates a potential turnaround for the telehealth company.

Hims & Hers Surges on Novo Obesity Deal That Ends Public Feud  Bloomberg.com

Barclays has lowered its price target on Hims & Hers Health, Inc. (HIMS) to $25 while keeping an Overweight rating.

After a 70% decline over the past year, questions arise about whether Hims & Hers Health stock can bounce back.

Hims & Hers experienced a significant drop in stock value at market open, attributed to regulatory issues that have negatively impacted its financial outlook for 2026.

Investors are reportedly worried about Hims & Hers' profitability due to its aggressive expansion plans, a recent Super Bowl ad, and increased legal and regulatory scrutiny over its weight-loss drug business.

Hims & Hers Health announced its latest financial results, with GAAP EPS of $0.08, surpassing estimates by $0.03, and revenue of $617.82M, which was in-line with expectations.

Hims & Hers forecasts first-quarter sales below estimates, shares fall  Reuters

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers, a telehealth platform, is set to acquire Australian health tech company Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers announced its plan to acquire Eucalyptus in a deal valued at $1.15 billion.

Hims & Hers has announced its intention to acquire Eucalyptus in a deal valued at $1.15 billion.

This report highlights key premarket movers in the US stock market, including Carvana, Deere, Hims & Hers, and Walmart.

Hims & Hers Health is being assessed for its potential for sustained long-term growth in the market.

The weight-loss drug market is rapidly expanding globally, with a shift from injections to pills and intense competition between pharmaceutical giants like Novo Nordisk and Eli Lilly. Regulatory scrutiny is also impacting new product offerings in this lucrative sector.